Simvastatin Reduces CD40 Expression in an Experimental Model of Early Arterialization of Saphenous Vein Graft

Journal of Surgical Research

Volumn 136, Issue 2, 2006, Pages 302-308

  Chello, Massimo ^a   Spadaccio, Cristiano ^a   Anselmi, Amedeo ^a   Patti, Giuseppe ^a   Lusini, Mario ^a   Di Sciascio, Germano ^a   Covino, Elvio ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

arterial grafts; endothelium; statins; thrombosis; vein grafts

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; N(G) NITROARGININE METHYL ESTER; SIMVASTATIN;

AGED; ARTERIAL PRESSURE; ARTERY GRAFT; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL WALL; CLINICAL ARTICLE; CONCENTRATION RESPONSE; GRAFT FAILURE; HUMAN; INFLAMMATION; INTERNAL MAMMARY ARTERY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULSE PRESSURE; SAPHENOUS VEIN; SAPHENOUS VEIN GRAFT; SUPERNATANT; UPREGULATION; VEIN GRAFT;

AGED; ANTICHOLESTEREMIC AGENTS; ANTIGENS, CD40; BLOOD PRESSURE; CD40 LIGAND; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MAMMARY ARTERIES; MIDDLE AGED; NITRIC OXIDE; SAPHENOUS VEIN; SIMVASTATIN; THROMBOSIS; UP-REGULATION;

EID: 33750965225     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2006.06.013     Document Type: Article

References (30)

1. Shuhaiber J.H., Evans A.N., Massad M.G., and Geha A.S. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Eur J Cardiothorac Surg 22 (2002) 387
2. Fitzgibbon G.M., Kafka H.P., Leach A.J., Keon W.J., Hooper G.D., and Burton J.R. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. JACC 28 (1996) 616
3. Chello M., Mastroroberto P., Frati G., et al. Pressure distension stimulates the expression of adhesion molecules in the human saphenous vein graft. Ann Thorac Surg 76 (2003) 453
4. Chello M., Mastroroberto P., Perticone F., Celi V., and Colonna A. Nitric oxide modulation of neutrophil-endothelium interaction: Difference between arterial and venous coronary bypass grafts. JACC 31 (1998) 823
5. Yang Z., Ruschitzka F., Rabelink T.J., et al. Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels. Implications for venous bypass graft failure. Circulation 95 (1997) 1870
6. Freedman J.E. CD40-CD40L and platelet function: Beyond hemostasis. Circ Res 92 (2003) 944
7. Cipollone F., Mezzetti A., Porrecca E., et al. Association between enhanced CD40L and prothrombotic state in hypercholesterolemia: Effects of statin therapy. Circulation 106 (2002) 399
8. Nannizzi-Alaimo L., Rubenstein L.H., Alves V.L., Leong G.Y., Phillips D.R., and Gold H.K. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 105 (2002) 2849
9. Schönbeck U., Varo N., Libby P., Buring J., and Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation 104 (2001) 2266
10. Heeschen C., Dimmeler E.S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104
11. Hollenbaugh D., Mischel-Petty N., Edwards C.P., et al. Expression of functional CD40 by vascular endothelial cells. J Exp Med 182 (1995) 33
12. Schonbeck U., Mach F., Sukhova G.K., et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: A role for CD40 signaling in plaque rupture?. Circ Res 81 (1997) 448
13. Murphy R.T., Foley J.B., Mulvihill N., Crean P., and Walsh M.J. Impact of pre-existing statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. Am J Cardiol 87 (2001) 446
14. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001
15. Datani M.I., Elnicki M., Jain A.C., and Gibson C.M. Effect of preoperative statin therapy and cardiac outcome after coronary artery bypass grafting. Am J Cardiol 86 (2000) 1128
16. Mulhaupt F., Matter C.M., Kwak B.R., et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 59 (2003) 755
17. Wagner A.H., Gebauer M., Güldenzoph B., and Hecker M. 3-Hydroxy-3-methylglutaryl coenzyme a reductase: Independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol 22 (2002) 1784
18. Golledge J., Turner R.J., Harley S.L., Springall D.R., and Powell J.T. Development of an in vitro model to study the response of saphenous vein endothelium to pulsatile arterial flow and circumferential deformation. Eur J Vasc Endovasc Surg 13 (1997) 605
19. Yan J.C., Wu Z.G., Li L., Zhong R.Q., and Kong X.T. Relationship between expression of CD40-CD40 ligand system and serum cholesterol levels in patients with hypercholesterolemia. Chin Med J 117 (2004) 1101
20. Sanguigni V., Pignatelli P., Lenti L., et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111 (2005) 412
21. Tan P.H., Chan C., Xue S.A., et al. Phenotypic and functional differences between human saphenous vein (HSVEC) and umbilical vein (HUVEC) endothelial cells. Atherosclerosis 173 (2004) 171
22. Szentivanyi Jr. M., Berczi V., Huttl T., Reneman R.S., and Monos E. Venous myogenic tone and its regulation through K+ channels depends on chronic intravascular pressure. Circ Res 81 (1997) 988
23. Phipps R.P. Atherosclerosis: The emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 97 (2000) 6930
24. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591
25. Inwald D.P., McDowall A., Peters M.J., Callard R.E., and Klein N.J. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 92 (2003) 1041
26. Aukrust P., Damas J.K., and Solum N.O. Soluble CD40 ligand and platelets: Self-perpetuating pathogenic loop in thrombosis and inflammation?. JACC 16 (2004) 2326
27. Lefer A.M., Scalia R., and Lefer D.J. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: New concept for cardiovascular disease. Cardiovasc Res 49 (2001) 281
28. Miller S.J. Emerging mechanisms for secondary cardioprotective effects of statins. Cardiovasc Res 52 (2001) 5
29. Garlichs C.D., John S., Schmeisser A., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104 (2001) 2395
30. Schonbeck U., Gerdes N., Varo N., et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 106 (2002) 2888